bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
All Web sites
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2014: A M F J
2013: D N O S A J J M A

 
  Other news for:
Hypertension
 Resources from HONselect
Common Blood Pressure Meds May Cut Risk of Early Death in Kidney Patients: Study
Drugs called ACE inhibitors and ARBs may help patients avoid dialysis as well, researchers say

By Robert Preidt

MONDAY, Dec. 16, 2013 (HealthDay News) -- Drugs that help lower blood pressure may reduce the risk of early death for people with advanced kidney disease, a new study finds.

The drugs could also lower patients' odds of requiring dialysis, the researchers said.

The new study out of Taiwan focused on two types of high blood pressure drugs, angiotensin-converting enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blockers (ARBs).

ACE inhibitors have long been a standby of blood pressure care, and include drugs such as Altace (ramipril), Vasotec (enalapril) and Lotensin (benazepril, among others). ARB medications are also used to lower blood pressure, and include medications such as Atacand (candesartan), Cozaar (losartan), and valsartan (Diovan, among others).

Both classes of drugs have been known to delay the progression of chronic kidney disease in patients with and without diabetes, the Taiwanese authors noted. However, most large studies of ACE inhibitors or ARBs have excluded patients with advanced chronic kidney disease, so it hasn't been known how these drugs affect this group of patients.

So, this new study included nearly 28,500 advanced chronic kidney disease patients with stable high blood pressure. During a follow-up of seven months, nearly 71 percent of the patients had to begin dialysis and 20 percent died before reaching that stage.

Patients who took an ACE inhibitor or an ARB had a 6 percent lower risk of dialysis or death than those who didn't take the drugs, according to the study published online Dec. 16 in the journal JAMA Internal Medicine.

"In conclusion, our findings expand the existing knowledge in the field and provide clinicians with new information," wrote Dr. Ta-Wei Hsu, of the National Yang-Ming University Hospital, and colleagues.

Dr. Sripal Bangalore is an assistant professor in the division of cardiology at NYU Langone Medical Center, in New York City. He said the study was long needed, because this type of patient has been "largely excluded from randomized trials."

The finding that these blood pressure medications can lower risks to patients is "a message often preached by nephrologists [kidney specialists], but rarely followed by others," Bangalore added.

He stressed, however, that the study is observational and cannot prove that the use of these medications caused the improvement in outcomes.

Still, "the important take-home message is that these agents potentially can delay the need for dialysis," Bangalore said, "but one should carefully follow these patients for hyperkalemia [an unhealthy build-up of potassium in the kidneys]."

More information

The National Kidney Foundation has more about chronic kidney disease.

SOURCES: Sripal Bangalore, M.D., assistant professor, department of medicine, Leon H. Charney Division of Cardiology, NYU Langone Medical Center, New York City; JAMA Internal Medicine, news release, Dec. 16, 2013

Copyright © 2013 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=683066

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Kidney
Blood
Risk
Specialty Chemicals and Products
Death
Dialysis
Kidney Diseases
Hypertension
Losartan
Research Personnel
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact